Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS NASDAQ:AKTX NASDAQ:CPIX NASDAQ:RGLS NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.08+1.3%$3.45$3.96▼$12.00$5.52M1.557,305 shs3,223 shsAKTXAkari Therapeutics$0.73-3.4%$0.96$0.57▼$3.85$23.88M0.2752,359 shs2.83 million shsCPIXCumberland Pharmaceuticals$3.39+0.7%$3.37$1.04▼$7.25$50.64M-0.37598,510 shs3,697 shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/ASNGXSoligenix$2.82+0.9%$2.49$1.09▼$6.23$12.08M2.054.07 million shs20,832 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%0.00%+8.07%-13.68%-25.96%AKTXAkari Therapeutics-2.64%-10.13%-25.24%-34.35%-76.91%CPIXCumberland Pharmaceuticals-0.59%-1.18%+7.35%-37.31%+168.80%RGLSRegulus Therapeutics0.00%0.00%0.00%-0.61%+416.46%SNGXSoligenix+1.45%+4.10%+0.36%+56.74%-20.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.08+1.3%$3.45$3.96▼$12.00$5.52M1.557,305 shs3,223 shsAKTXAkari Therapeutics$0.73-3.4%$0.96$0.57▼$3.85$23.88M0.2752,359 shs2.83 million shsCPIXCumberland Pharmaceuticals$3.39+0.7%$3.37$1.04▼$7.25$50.64M-0.37598,510 shs3,697 shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/ASNGXSoligenix$2.82+0.9%$2.49$1.09▼$6.23$12.08M2.054.07 million shs20,832 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%0.00%+8.07%-13.68%-25.96%AKTXAkari Therapeutics-2.64%-10.13%-25.24%-34.35%-76.91%CPIXCumberland Pharmaceuticals-0.59%-1.18%+7.35%-37.31%+168.80%RGLSRegulus Therapeutics0.00%0.00%0.00%-0.61%+416.46%SNGXSoligenix+1.45%+4.10%+0.36%+56.74%-20.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AAKTXAkari Therapeutics 3.00Buy$3.30352.67% UpsideCPIXCumberland Pharmaceuticals 0.00N/AN/AN/ARGLSRegulus Therapeutics 2.17Hold$8.807.84% UpsideSNGXSoligenix 3.00Buy$6.00113.14% UpsideCurrent Analyst Ratings BreakdownLatest AEZS, RGLS, CPIX, AKTX, and SNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.607/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.007/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.33N/AN/A$14.99 per share0.21AKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACPIXCumberland Pharmaceuticals$37.87M1.34$0.26 per share13.14$1.61 per share2.10RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ASNGXSoligenix$120K100.64N/AN/A$1.64 per share1.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%N/AAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%9/25/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/ASNGXSoligenix-$8.27M-$3.80N/AN/AN/AN/A-274.76%-129.20%11/14/2025 (Estimated)Latest AEZS, RGLS, CPIX, AKTX, and SNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025AKTXAkari Therapeutics-$0.09N/AN/AN/AN/AN/A8/14/2025Q2 2025SNGXSoligenix-$0.79-$0.82-$0.03-$0.82N/AN/A8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93AKTXAkari TherapeuticsN/A0.190.19CPIXCumberland Pharmaceuticals0.191.301.17RGLSRegulus TherapeuticsN/A16.3116.31SNGXSoligenixN/A1.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%AKTXAkari Therapeutics5.06%CPIXCumberland Pharmaceuticals15.51%RGLSRegulus Therapeutics92.38%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%AKTXAkari Therapeutics38.10%CPIXCumberland Pharmaceuticals44.85%RGLSRegulus Therapeutics4.35%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableSNGXSoligenix204.29 million4.16 millionNot OptionableAEZS, RGLS, CPIX, AKTX, and SNGX HeadlinesRecent News About These CompaniesSoligenix Tumbles After Company Publishes PaperSeptember 4, 2025 | baystreet.caSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related VirusesSeptember 4, 2025 | prnewswire.comSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comSoligenix Inc. Reports Q2 2025 Earnings LossAugust 22, 2025 | msn.comCompanies Like Soligenix (NASDAQ:SNGX) Could Be Quite RiskyAugust 21, 2025 | finance.yahoo.comWhy Is Soligenix Stock Soaring On Monday?August 18, 2025 | benzinga.comSoligenix’s dusquetide granted Orphan Drug Designation in Behcet’s DiseaseAugust 18, 2025 | msn.comSoligenix Shares Surge After FDA Grants Orphan Drug StatusAugust 18, 2025 | msn.comSoligenix stock soars after FDA grants orphan drug designationAugust 18, 2025 | za.investing.comFDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study ResultsAugust 18, 2025 | prnewswire.comSoligenix Faces Nasdaq Non-Compliance NoticeAugust 16, 2025 | msn.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deSoligenix receives FDA orphan designation for dusquetideAugust 14, 2025 | msn.comSoligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL TherapyAugust 8, 2025 | finance.yahoo.comNetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin CancerAugust 8, 2025 | globenewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Completes Phase 2a Study for SGX945August 6, 2025 | theglobeandmail.comSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL SpaceAugust 5, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEZS, RGLS, CPIX, AKTX, and SNGX Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.08 +0.04 (+1.32%) As of 09/2/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Akari Therapeutics NASDAQ:AKTX$0.73 -0.03 (-3.44%) As of 10:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cumberland Pharmaceuticals NASDAQ:CPIX$3.38 +0.03 (+0.74%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Soligenix NASDAQ:SNGX$2.82 +0.03 (+0.90%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
